<DOC>
	<DOCNO>NCT01274598</DOCNO>
	<brief_summary>This phase I , open label clinical trial evaluate safety Lactobacillus rhamnosus GG ( LGG ) elderly subject . Lactobacilli part normal flora intestine . LGG one several strain Lactobacilli use probiotic microorganism administer confer `` health benefit '' . Our research focus study possible therapeutic effect LGG . The study hypotheses : - LGG administer twice daily safe well tolerate elderly subject - LGG colonize stool elderly subject modify diversity richness microbiota nasopharyngeal stool specimen</brief_summary>
	<brief_title>Study Evaluate Safety Lactobacillus Rhamnosus GG ATCC 53103 ( LGG ) Elderly Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Age 6580 year 2 . Willing complete informed consent process 3 . Able willing participate plan duration study , include availability followup telephone contact 4 . Willing comply protocol report compliance side effect study period 5 . Informed consent obtain sign prior screen 1 . Consumption supplement food product contain LGG probiotic 28 day prior start study consumption yogurt `` live active culture '' seal . 2 . Known suspected allergy probiotic , Lactobacillus , microcrystalline cellulose , gelatin , antibiotic may use treat LGG bacteremia infection ( i.e. , subject able tolerate least 2 follow regimen Ampicillin beta lactam antibiotic , Clindamycin , Moxifloxacin ) . 3 . Received oral parenteral antibiotic within 4 week enrollment prescribed antibiotic day enrollment 4 . Drug alcohol abuse within previous 12 month 5 . Hospitalization , major surgery endoscopy within last 3 month 6 . Scheduled hospital admission within 3 month enrollment 7 . Resident nursing home rehabilitation center 8 . Presence follow : Grade 2 high abnormal vital sign abnormality physical exam Indwelling catheter implant hardware/prosthetic device feed tube Active bowel leak , acute abdomen , colitis , active GI disease history gastric intestinal dysmotility , slow transit time , variable small intestinal permeability , pancreatitis , history gastrointestinal tract cancer inflammatory bowel disease History Hepatitis B Hepatitis C infection , cirrhosis , chronic liver disease Underlying structural heart disease abnormal native heart valve congenital abnormality , previous history endocarditis valve replacement , Stage IV congestive heart failure History peripheral vascular disease stroke Immunosuppression include HIV positive , solid organ stem cell transplant recipient , receive oral parenteral immunosuppressive therapy , neutrophil count &lt; 500/mm3 , anticipate drop neutrophil count &lt; 500/mm3 active plan chemotherapy radiotherapy History collagen vascular autoimmune disease End stage renal disease History chronic obstructive pulmonary disease asthma Diabetes thyroid disease Active TB 9 . Positive drug alcohol test screen positive breathalyzer baseline unwillingness undergo drug alcohol test 10 . Abnormal laboratory test define follow : White blood cell ( WBC ) &lt; 3.3 &gt; 12.0 K/µL Platelets &lt; 125 K/µL Hemoglobin Males : &lt; 12.0 g/dL ; Females : &lt; 11.0 g/dL Creatinine &gt; 1.8 mg/dL Blood urea nitrogen ( BUN ) &gt; 27 mg/dL Aspartate aminotransferase ( AST ) &gt; 1.25 ULN Alanine aminotransferase ( ALT ) &gt; 1.25 ULN Alkaline phosphatase &gt; 2.0 ULN Bilirubin ( total ) &gt; 1.5 ULN Glucose ( nonfasting ) &gt; 126 mg/dL Positive HIV , Hepatitis B surface antigen Hepatitis C antibody 11 . Any condition opinion investigator would jeopardize safety right subject participate study would make unlikely subject could complete study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Probiotics</keyword>
	<keyword>Safety</keyword>
	<keyword>Elderly</keyword>
	<keyword>Lactobacillus</keyword>
	<keyword>LGG</keyword>
</DOC>